Cancer Immunotherapy Market Surges to USD 217.9 Billion by 2030, Reflecting an 8.6% Growth | MarketDigits
February 14, 2024 07:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 14, 2024 (GLOBE NEWSWIRE) -- According to a research report "Cancer Immunotherapy Market”, by Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors {CTLA-4, PD-1/PD-L1},...
Immunomodulators Global Market Likely to Exhibit Substantial Growth at a CAGR of ~5% by 2028 | DelveInsight
June 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, June 19, 2023 (GLOBE NEWSWIRE) -- Immunomodulators Global Market Likely to Exhibit Substantial Growth at a CAGR of ~5% by 2028 | DelveInsight The immunomodulators market is...
Cancer Immunotherapy Market Is Expected to Reach $309.67 Billion by 2030, Grow at a CAGR Of 9.6% during Forecast Period 2023 To 2030 | Data By Contrive Datum Insights Pvt Ltd.
April 11, 2023 15:22 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, April 11, 2023 (GLOBE NEWSWIRE) -- The Global Cancer Immunotherapy Market Was Valued At $85.6 Billion In 2022 And Is Expected To Expand $309.67 Billion By 2030 at a CAGR Of 9.6% From...
Global Cancer Immunotherapy Market to Surpass US$ 216,792.7 Million by 2030, Says Coherent Market Insights (CMI)
January 23, 2023 09:00 ET
|
CMI
Burlingame, Jan. 23, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Cancer Immunotherapy Market is estimated to be valued at US$ 102,095.5 million in 2022 and is expected to...
Global Biosimilar Market to Gather $83,836.40 Million by 2028, Growing at a CAGR of 24.90% in the 2021-2028 Timeframe [170-Pages] | Issued by Research Dive
January 03, 2023 09:02 ET
|
Research Dive
New York, USA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global biosimilar market is expected to gather a revenue of $83,836.40 million by...
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient
August 27, 2021 12:46 ET
|
BioAegis Therapeutics
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Cancer Immunotherapy Market Worth $152.83 Billion by 2024 - Exclusive Report by Meticulous Research®
October 30, 2018 09:18 ET
|
Meticulous Market Research Pvt. Ltd.
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- According to the latest publication from Meticulous Research®, the global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to...
Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer
February 04, 2015 10:05 ET
|
Qu Biologics;BC Cancer Agency
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...